French biotech Cor­te­ria se­cures $70M to re­vive ex-Sanofi heart drugs 

In­vestors are pump­ing $70 mil­lion in­to a Paris-based biotech’s at­tempt to re­vive two of Sanofi’s for­mer car­dio­vas­cu­lar pro­grams.

Cor­te­ria Phar­ma­ceu­ti­cals, found­ed in 2021, on Thurs­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER